Mutual of America Capital Management’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,654
| Closed | -$65.5K | – | 1390 |
|
|
2025
Q4 | $65.5K | Buy |
10,654
+231
| +2% | +$1.68K | ﹤0.01% | 1354 |
|
|
2025
Q3 | $75.4K | Sell |
10,423
-1,418
| -12% | -$8.42K | ﹤0.01% | 1345 |
|
|
2025
Q2 | $62.9K | Sell |
11,841
-1,416
| -11% | -$8.36K | ﹤0.01% | 1368 |
|
|
2025
Q1 | $118K | Sell |
13,257
-533
| -4% | -$6.4K | ﹤0.01% | 1389 |
|
|
2024
Q4 | $189K | Buy |
13,790
+130
| +1% | +$2.4K | ﹤0.01% | 1390 |
|
|
2024
Q3 | $374K | Sell |
13,660
-1,217
| -8% | -$32.9K | ﹤0.01% | 1228 |
|
|
2024
Q2 | $364K | Sell |
14,877
-376
| -2% | -$8.25K | ﹤0.01% | 1223 |
|
|
2024
Q1 | $325K | Sell |
15,253
-266
| -2% | -$5.72K | ﹤0.01% | 1283 |
|
|
2023
Q4 | $297K | Buy |
15,519
+1,167
| +8% | +$20.2K | ﹤0.01% | 1301 |
|
|
2023
Q3 | $230K | Sell |
14,352
-1,577
| -10% | -$30K | ﹤0.01% | 1339 |
|
|
2023
Q2 | $369K | Sell |
15,929
-758
| -5% | -$16.5K | ﹤0.01% | 1222 |
|
|
2023
Q1 | $388K | Sell |
16,687
-296
| -2% | -$6.01K | ﹤0.01% | 1196 |
|
|
2022
Q4 | $246K | Buy |
16,983
+940
| +6% | +$17.5K | ﹤0.01% | 1333 |
|
|
2022
Q3 | $306K | Buy |
16,043
+2,549
| +19% | +$58.5K | ﹤0.01% | 1225 |
|
|
2022
Q2 | $245K | Buy |
13,494
+1,987
| +17% | +$41.3K | ﹤0.01% | 1267 |
|
|
2022
Q1 | $290K | Buy |
11,507
+597
| +5% | +$15.3K | ﹤0.01% | 1227 |
|
|
2021
Q4 | $301K | Buy |
10,910
+501
| +5% | +$14.5K | ﹤0.01% | 1229 |
|
|
2021
Q3 | $336K | Sell |
10,409
-545
| -5% | -$18.1K | ﹤0.01% | 1199 |
|
|
2021
Q2 | $335K | Buy |
10,954
+910
| +9% | +$26.3K | ﹤0.01% | 1245 |
|
|
2021
Q1 | $306K | Buy |
10,044
+647
| +7% | +$18.4K | ﹤0.01% | 1253 |
|
|
2020
Q4 | $186K | Buy |
9,397
+392
| +4% | +$6.33K | ﹤0.01% | 1306 |
|
|
2020
Q3 | $117K | Buy |
9,005
+5,396
| +150% | +$68.3K | ﹤0.01% | 1354 |
|
|
2020
Q2 | $41K | Buy |
3,609
+334
| +10% | +$4.74K | ﹤0.01% | 1394 |
|
|
2020
Q1 | $47K | Buy |
3,275
+636
| +24% | +$13.4K | ﹤0.01% | 1302 |
|
|
2019
Q4 | $72K | Sell |
2,639
-139
| -5% | -$3.82K | ﹤0.01% | 1257 |
|
|
2019
Q3 | $80K | Buy |
2,778
+152
| +6% | +$4.43K | ﹤0.01% | 1237 |
|
|
2019
Q2 | $73K | Buy |
2,626
+529
| +25% | +$14.9K | ﹤0.01% | 1249 |
|
|
2019
Q1 | $70K | Buy |
2,097
+273
| +15% | +$8.31K | ﹤0.01% | 1213 |
|
|
2018
Q4 | $53K | Buy |
1,824
+475
| +35% | +$17.1K | ﹤0.01% | 1226 |
|
|
2018
Q3 | $62K | Buy |
1,349
+1,092
| +425% | +$48.6K | ﹤0.01% | 1211 |
|
|
2018
Q2 | $10K | Buy |
+257
| New | +$8.68K | ﹤0.01% | 1243 |
|
Other funds holding MYGN
O
GCM
Mutual of America Capital Management's MYGN Position: Q1 2026 in Review
Mutual of America Capital Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 10,654 shares — an estimated $65.5K sold.
Mutual of America Capital Management first reported a position in MYGN in Q2 2018 and held it in 31 quarters. The position peaked at $388K in Q1 2023. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- Mutual of America Capital Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
- Mutual of America Capital Management sold 10,654 Myriad Genetics shares in Q1 2026, an estimated $65.5K.
- Mutual of America Capital Management first reported a position in Myriad Genetics in Q2 2018 and held it in 31 quarters.
- Mutual of America Capital Management's Myriad Genetics position peaked at $388K in Q1 2023.
- 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on Mutual of America Capital Management's 13F filing for Q1 2026, filed 7 May 2026.